Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
Abstract
Characterization of MAbs against SARS-CoV-2, elicited through vaccination or natural infection, has provided vital immunotherapeutic options for curbing the COVID-19 pandemic and has supplied critical insights into SARS-CoV-2 escape, transmissibility, and mechanisms of viral inactivation. Neutralizing MAbs that target the RBD but do not block ACE2 binding are of particular interest because the epitopes are well conserved within sarbecoviruses and MAbs targeting this area demonstrate cross-reactivity.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 27, 2023
- Source ID
- 10.1128/jvi.01596-22
Entities
People
- Agnes Hajduczki
- Benjamin J Doranz
- Caroline E. Peterson
- Edgar Davidson
- Elizabeth J. Martinez
- Emily S. Golub
- Erin Kavusak
- Eun Sung Yang
- Gregory D. Gromowski
- Hongjun Bai
- Jaime L. Jensen
- Kayvon Modjarrad
- Kerri G Lal
- Letzibeth Mendez-rivera
- Lindsay Wieczorek
- Lingshu Wang
- M Gordon Joyce
- Man Chen
- Michelle Zemil
- Misook Choe
- Morgane Rolland
- Nelson Michael
- Phyllis A. Rees
- Rajeshwer S. Sankhala
- Richard A. Koup
- Sandra V. Mayer
- Shelly J. Krebs
- Shruthi Kannan
- Victoria R. Polonis
- Vincent Dussupt
- William C Chang
- Yi Zhang
Organizations
- Defense Health Agency
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Integral Molecular
- National Institutes of Health
- Walter Reed Army Institute of Research